BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3484240)

  • 1. Measurement of serum CA 125 in ovarian cancers.
    Yuan CC; Ng HT; Yeh SH; Jeng FS; Chen SL; Tsai LC
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Mar; 39(3):153-60. PubMed ID: 3484240
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expression of CA-125 in ovarian cancer].
    Mircea R; Frîncu DL; Dumitrache F
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
    Nagele F; Vavra N; Kurz C; Sevelda P
    Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
    Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
    Koebl H; Tatra G; Bieglmayer C
    Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidence of CA 125 antigen in the blood of women with ovarian carcinoma].
    Tosner J; Lacinová V; Louda B; Vanásek J
    Cesk Gynekol; 1987 Nov; 52(9):681-4. PubMed ID: 3482173
    [No Abstract]   [Full Text] [Related]  

  • 9. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
    Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
    Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
    Crombach G; Zippel HH; Würz H
    Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
    Patsner B; Mann WJ; Chalas E
    Obstet Gynecol; 1988 Jun; 71(6 Pt 1):949-50. PubMed ID: 3163416
    [No Abstract]   [Full Text] [Related]  

  • 12. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Definition, diagnosis and treatment of ovarian cancers at an early stage].
    Terashima Y; Yokoyama S; Kimura E
    Nihon Rinsho; 1989 May; 47(5):1165-71. PubMed ID: 2746909
    [No Abstract]   [Full Text] [Related]  

  • 14. [Serum level of the tumor marker CA 125 in ovarian pathology].
    Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
    Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
    Suzuki M; Sekiguchi I; Tamada T
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
    Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
    J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Carcinoma of the ovary: reliability of its markers].
    Moggian G; Gunelli R; Magrone F; Canali P; Spadazzi AP; Pini PL
    Minerva Ginecol; 1988 Jan; 40(1):9-13. PubMed ID: 3163780
    [No Abstract]   [Full Text] [Related]  

  • 18. Roles of CA125 in patients with ovarian cancer--usefulness in periodical monitoring.
    Kawai M; Inagaki S; Yamashita H; Imaizumi H; Kakihara M; Arii Y
    Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1059-67. PubMed ID: 3166484
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experiences with the tumor markers Ca 125 and plasma ribonuclease in ovarian cancer].
    Lücke R; Benz R; Kraus H
    Geburtshilfe Frauenheilkd; 1987 Dec; 47(12):846-9. PubMed ID: 3481339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.